Evidence map›Paper›PMID 37900367›Full record

ArticleCureus2023

Psychotropic Medication Adherence and Its Associated Factors Among Schizophrenia Patients: Exploring the Consistency of Adherence Scales.

Maghzoub M Ali, Manal M Taha, Anas E Ahmed, Suhaila Ali, Maisa A Baiti, Atyaf A Alhazmi, Bushra A Alfaifi, Rania Q Majrabi, Nidaa Q Khormi, Alyaj A Hakami and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Maghzoub M AliMedical Research Center, Jazan University, Jazan, SAU.
Manal M TahaMedical Research Center, Jazan University, Jazan, SAU.
Anas E AhmedCollege of Medicine, Jazan University, Jazan, SAU.
Suhaila AliCollege of Medicine, Jazan University, Jazan, SAU.
Maisa A BaitiCollege of Medicine, Jazan University, Jazan, SAU.
Atyaf A AlhazmiCollege of Medicine, Jazan University, Jazan, SAU.
Bushra A AlfaifiCollege of Medicine, Jazan University, Jazan, SAU.
Rania Q MajrabiCollege of Medicine, Jazan University, Jazan, SAU.
Nidaa Q KhormiCollege of Medicine, Jazan University, Jazan, SAU.
Alyaj A HakamiCollege of Medicine, Jazan University, Jazan, SAU.
Rafa A AlqaariCollege of Medicine, Jazan University, Jazan, SAU.
Raffan A AlhasaniCollege of Medicine, Jazan University, Jazan, SAU.
Siddig I AbdelwahabMedical Research Center, Jazan University, Jazan, SAU.
Jazan University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and objective Non-adherence to psychotropic medication can aggravate an individual's illness, diminish treatment efficacy, or make patients less responsive to future therapeutic interventions. There are several scales available to measure non-adherence to medications. In this study, we aimed to measure psychotropic medication adherence and its associated factors among schizophrenic outpatients in Saudi Arabia. Methodology A cross-sectional study was conducted with a view to measuring psychotropic medication adherence and its associated factors. The Medication Adherence Rating Scale (MARS) and the Drug Attitude Inventory-10 (DAI-10) were translated into Arabic, and their internal consistency was measured. The adjusted odds ratios (AOR) were calculated using logistic regression in the IBM SPSS Statistics software version 23 (IBM Corp., Armonk, NY). Results Spearman's rho correlation indicated a negative association between DAI-10 and MARS scores (r = -0.579; p<0.05). The Arabic version of MARS was more reliable than DAI-10, as evidenced by Cronbach's alpha value. Of note, 60.20% (n = 59) of the sample demonstrated high adherence levels. The adherence level based on MARS scoring remained unaffected (p>0.05) in terms of gender, age, employment, marital status, educational level, income level, and duration of sickness. These results were obtained by using the multivariate logistic regression model; 89% of respondents reported not using psychiatric drugs given by someone else, despite the adherence rate not affecting this number. Conclusion The rate of non-adherence to psychotropic treatment was found to be high in our cohort. Hence, it is imperative to develop comprehensive intervention methods targeting the causes of non-adherence to psychiatric medication.

Indexed as

adherence scalesinternal consistencymedication adherencescalesschizophrenia

Identifiers

PMID37900367
PMCPMC10612138
OpenAlexW4387137620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.